Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26

Reuters03-23

<a href="https://laohu8.com/S/CABA">Cabaletta Bio</a> expects initial RESET-SLE no-preconditioning rese-cel data in 1H26

Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials.
Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel without preconditioning are expected to be presented in 1H26, with durability data expected in 2H26.
Dose-ranging durability data from RESET-PV without preconditioning are anticipated throughout 2026, supplementing previously presented low-dose pemphigus vulgaris data.
Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG evaluating rese-cel with preconditioning are expected to be presented in 1H26.
Cabaletta expects to report initial clinical experience in 1H26 with rese-cel manufactured using the Cellares Cell Shuttle platform, with longer-term clinical data expected in 2H26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001759138-26-000010), on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621702770?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621702770","market":"us","top_or_hot":-1,"title":"Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> expects initial RESET-SLE no-preconditioning rese-cel data in 1H26\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials.\n        </li>\n<li>\n          Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel without preconditioning are expected to be presented in 1H26, with durability data expected in 2H26.\n        </li>\n<li>\n          Dose-ranging durability data from RESET-PV without preconditioning are anticipated throughout 2026, supplementing previously presented low-dose pemphigus vulgaris data.\n        </li>\n<li>\n          Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG evaluating rese-cel with preconditioning are expected to be presented in 1H26.\n        </li>\n<li>\n          Cabaletta expects to report initial clinical experience in 1H26 with rese-cel manufactured using the Cellares Cell Shuttle platform, with longer-term clinical data expected in 2H26.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001759138-26-000010), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/CABA\">Cabaletta Bio</a> expects initial RESET-SLE no-preconditioning rese-cel data in 1H26\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials.\n        </li>\n<li>\n          Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel without preconditioning are expected to be presented in 1H26, with durability data expected in 2H26.\n        </li>\n<li>\n          Dose-ranging durability data from RESET-PV without preconditioning are anticipated throughout 2026, supplementing previously presented low-dose pemphigus vulgaris data.\n        </li>\n<li>\n          Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG evaluating rese-cel with preconditioning are expected to be presented in 1H26.\n        </li>\n<li>\n          Cabaletta expects to report initial clinical experience in 1H26 with rese-cel manufactured using the Cellares Cell Shuttle platform, with longer-term clinical data expected in 2H26.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001759138-26-000010), on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CABA","symbol_name":"Cabaletta Bio","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6VvJl8:1","article_id":"2621702770","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621702770","pubTimestamp":1774265615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials.Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel without preconditioning are expected to be presented in 1H26, with durability data expected in 2H26.Dose-ranging durability data from RESET-PV without preconditioning are anticipated throughout 2026, supplementing previously presented low-dose pemphigus vulgaris data.Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG evaluating rese-cel with preconditioning are expected to be presented in 1H26.Cabaletta expects to report initial clinical experience in 1H26 with rese-cel manufactured using the Cellares Cell Shuttle platform, with longer-term clinical data expected in 2H26.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated con","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CABA":"Cabaletta Bio","BK4139":"生物科技"},"translate_title":"Cabaletta Bio预计在1H26获得初始重置-SLE无预处理rese-cel数据","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CABA":0.9},"content_text":"Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26\n    \n\n\n          Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials.\n        \n\n          Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel without preconditioning are expected to be presented in 1H26, with durability data expected in 2H26.\n        \n\n          Dose-ranging durability data from RESET-PV without preconditioning are anticipated throughout 2026, supplementing previously presented low-dose pemphigus vulgaris data.\n        \n\n          Complete Phase 1/2 data from RESET-SLE, RESET-SSc, and RESET-MG evaluating rese-cel with preconditioning are expected to be presented in 1H26.\n        \n\n          Cabaletta expects to report initial clinical experience in 1H26 with rese-cel manufactured using the Cellares Cell Shuttle platform, with longer-term clinical data expected in 2H26.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cabaletta Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001759138-26-000010), on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621702770","isCrawlerRequest":true}